Ultimovacs ASA (ULTI.OL)

7.85 +0.05 (+0.64%) At close: 04:25PM CEST

Ultimovacs ASA

Ullernchausséen 64
Oslo 0379
Norway
47 41 38 00 80
https://www.ultimovacs.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 25

Description

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Corporate governance

Ultimovacs ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.